Emily Jacobs, MD
Urology · Jonesboro, ARNPI 1558673889
Payments from drug & device makers
What this record shows
The money is spread across several categories — ownership interests (49.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Ozark Cryosurgery, LLC at 49.5% of the total. Reporting peaked in 2019 at $11,569 and has fallen 70.3% since, to $3,433 in 2025.
Across 332 payments — averaging $111.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ozark Cryosurgery, LLC$18K
- EDAP Technomed Inc$7K
- Medtronic$6K
- Procept Biorobotics Corporation$1K
- Neotract Inc.$897
- Boston Scientific$500
- plus $3K from 32 others
What the payments were for
- Travel & lodging$8,90224%
- Food & beverage$9,24125%
- Education$1921%
- Entertainment$3251%
- Ownership interest$18,31250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ozark Cryosurgery, LLC | 3 | $18,312 |
| EDAP Technomed Inc | 32 | $7,075 |
| Medtronic(2 entities) | 96 | $5,547 |
| Procept Biorobotics Corporation | 14 | $1,289 |
| Neotract Inc. | 3 | $897 |
| Boston Scientific | 13 | $500 |
| Astellas Pharma US Inc | 23 | $462 |
| AbbVie(2 entities) | 25 | $442 |
| Urogen Pharma, Inc. | 7 | $267 |
| Coloplast | 10 | $259 |
| Myovant Sciences Inc. | 13 | $189 |
| Sumitomo Pharma America, Inc. | 10 | $176 |
| Pfizer | 11 | $174 |
| Dendreon Pharmaceuticals LLC | 10 | $166 |
| Johnson & Johnson | 12 | $155 |
| Axonics, Inc. | 4 | $129 |
| Blue Earth Diagnostics | 7 | $127 |
| Myriad Genetic Laboratories, Inc. | 3 | $116 |
| Merck | 5 | $85 |
| Amgen | 5 | $65 |
| Tolmar, Inc. | 3 | $53 |
| Tolmar Pharmaceuticals, Inc. | 3 | $50 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $50 |
| Conmed Corporation | 1 | $49 |
| Teleflex LLC | 2 | $46 |
| Stryker | 1 | $45 |
| Endo Pharmaceuticals Inc. | 3 | $42 |
| Bayer | 2 | $36 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $22 |
| ABC Home Medical Supply, Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $19 |
| Civco Medical Instruments | 1 | $16 |
| Ambu Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Photocure Inc | 1 | $13 |
| Angiodynamics, Inc. | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,992
- AquaBeam Robotic System$1,007
- UroLift$897
- FOCAL ONE$753
- ALTAVIVA$650
- Axonics$124
- SPEEDICATH$103
How this compares
$36,973 in reported general payments places this provider in the 85th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 46 | $597,018 |
| NubeqaDarolutamide | 12 | $158,433 |
| MyrbetriqMirabegron | 157 | $85,624 |
| GemtesaVibegron | 28 | $13,711 |
| Estradiol | 115 | $7,401 |
| Solifenacin Succinate | 231 | $5,913 |
| Tamsulosin Hcl | 271 | $3,038 |
| Methenamine Hippurate | 41 | $1,591 |
| Finasteride | 61 | $953 |
| Cephalexin | 218 | $804 |
| Oxybutynin Chloride | 75 | $682 |
| Tolterodine Tartrate ErTolterodine Tartrate | 18 | $665 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 46 | $658 |
| NitrofurantoinNitrofurantoin Macrocrystal | 24 | $570 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $155 | $597,01846 claims |
| BayerNubeqa | $36 | $158,43312 claims |
| Astellas Pharma US IncMyrbetriq | $462 | $85,624157 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $176 | $13,71128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 88 urology providers in Arkansas.
Other urology in Jonesboro
- Rudolph BowensJonesboro$21K
- Joseph KueterJonesboro$21K
- Ladd ScriberJonesboro$7K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.